Characterizing the Intraocular Scattering at Different Wavelengths
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Study Contact
- Phone Number: 1-800-843-2020
- Email: tkarkkai@its.jnj.com
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77204
- University of Houston College of Optometry
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Potential subjects must satisfy all the following criteria to be enrolled in the study:
- Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Be at least 18 years of age and not greater than 75 years of age at the time of consent.
- Has had an eye examination within the last two years.
- The subject's distance vertex corrected spherical equivalent refraction must be in the range of +4.00 D to -6.00 D in each eye.
- The subject's refractive cylinder must be ≤2.50 D in each eye.
- The subject must have distance best corrected visual acuity of 20/25 or better in each eye.
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Be currently pregnant or lactating.
- Have any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with their ocular health. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g., hepatitis, tuberculosis).
- Have any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.).
- Use of any of the following medications within 1 week prior to enrollment: oral retinoid, oral tetracyclines, anticholinergics, oral phenothiazines, oral/inhaled corticosteroids, monoamine oxide inhibitors. See Section 9.1 for further examples.
- Use of any ocular medication that may interfere with study procedures as determined by the Investigator.
- Have a history of irregular cornea.
- Have a history of moderate to severe dry eye.
- Have Participated in clinical trial within 7 days prior to study enrollment.
- Be and employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
- Have any contraindications to pupil dilation.
- Have any known hypersensitivity, allergic reaction or other contraindication to proparacaine, tropicamide, phenylephrine or sodium fluorescein.
- Have any allergies to dental mold materials or contraindications to having a dental mold made.
- Have clinically significant (Grade 3 or greater) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities that may interfere with the study measurements.
- Have any ocular scars in the central 6 mm of the cornea that may interfere with the study measurement.
- Have any current ocular infection or inflammation.
- Intraocular pressure > 21mmHg OD or OS.
- Ocular angle assessed by Van Herick measurement of grade 2 or less OD or OS.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 770 +/- 9nm/ 830 +/- 15nm/ 900 +/- 15nm
Eligible subjects will be randomized to wavelength sequence 770 +/- 9nm/ 830 +/- 15nm/ 900 +/- 15nm.
Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm).
Study endpoints will be measured at 3 different pupil sizes.
|
Subjects will have their higher and lower order aberrations corrected with the AO system.
|
|
Experimental: 770 +/- 9nm/ 900 +/- 15nm/ 830 +/- 15nm
Eligible subjects will be randomized to wavelength sequence 770 +/- 9nm/ 900 +/- 15nm/ 830 +/- 15nm.
Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm).
Study endpoints will be measured at 3 different pupil sizes.
|
Subjects will have their higher and lower order aberrations corrected with the AO system.
|
|
Experimental: 830 +/- 15nm/ 770 +/- 9nm/ 900 +/- 15nm
Eligible subjects will be randomized to wavelength sequence 830 +/- 15nm/ 770 +/- 9nm/ 900 +/- 15nm.
Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm).
Study endpoints will be measured at 3 different pupil sizes.
|
Subjects will have their higher and lower order aberrations corrected with the AO system.
|
|
Experimental: 830 +/- 15nm/ 900 +/- 15nm/ 770 +/- 9nm
Eligible subjects will be randomized to wavelength sequence 830 +/- 15nm/ 900 +/- 15nm/ 770 +/- 9nm.
Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm).
Study endpoints will be measured at 3 different pupil sizes.
|
Subjects will have their higher and lower order aberrations corrected with the AO system.
|
|
Experimental: 900 +/- 15nm/ 830 +/- 15nm/ 770 +/- 9nm
Eligible subjects will be randomized to wavelength sequence 900 +/- 15nm/ 830 +/- 15nm/ 770 +/- 9nm.
Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm).
Study endpoints will be measured at 3 different pupil sizes.
|
Subjects will have their higher and lower order aberrations corrected with the AO system.
|
|
Experimental: 900 +/- 15nm/ 770 +/- 9nm/ 830 +/- 15nm
Eligible subjects will be randomized to wavelength sequence 900 +/- 15nm/ 770 +/- 9nm/ 830 +/- 15nm.
Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm).
Study endpoints will be measured at 3 different pupil sizes.
|
Subjects will have their higher and lower order aberrations corrected with the AO system.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Point Spread Function (PSF) for 3mm
Time Frame: up to 2-week follow-up
|
Point spread function will be collected in one eye at each Visits 2, 3 and 4 for 3mm pupil size for the assigned wavelength at that visit.
The PSF is defined as the way an optical system blurs a point source of light.
|
up to 2-week follow-up
|
|
Point Spread Function (PSF) for 4 mm
Time Frame: up to 2-week follow-up
|
Point spread function will be collected in one eye at each Visits 2, 3 and 4 for 4mm pupil size for the assigned wavelength at that visit.
The PSF is defined as the way an optical system blurs a point source of light.
|
up to 2-week follow-up
|
|
Point Spread Function (PSF) for 6 mm
Time Frame: up to 2-week follow-up
|
Point spread function will be collected in one eye at each Visits 2, 3 and 4 for 6mm pupil size for the assigned wavelength at that visit.
The PSF is defined as the way an optical system blurs a point source of light.
|
up to 2-week follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Johnson & Johnson Vision Care Clinical Trial, Johnson & Johnson Vision Care
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CR-6476
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.